This statistic shows the epidemiology of chronic hepatitis B in eight countries representing the major pharmaceutical markets worldwide in 2014. In these countries combined, the population number aged 18 years and older with chronic hepatitis B was 34.5 million.
Combined epidemiology of chronic hepatitis B in 8 major pharmaceutical markets in 2014*
Basic Account
Get to know the platform
You only have access to basic statistics.
This statistic is not included in your account.
Starter Account
The ideal entry-level account for individual users
- Instant access to 1m statistics
- Download in XLS, PDF & PNG format
- Detailed references
$199 USD / Month *
Professional Account
Full access
Business Solutions including all features.
* Prices do not include sales tax.
Other statistics that may interest you Pharmaceutical market worldwide
Overview
5
- Premium Statistic Pharmaceutical market: worldwide revenue 2001-2023
- Premium Statistic World pharmaceutical sales 2020-2023 by region
- Premium Statistic World pharmaceutical market distribution by submarket 2014-2023
- Premium Statistic Revenues of top 10 global pharmaceutical markets 2022
- Basic Statistic Top pharmaceutical products by sales worldwide 2023
Segments
7
- Premium Statistic Top therapy classes by spending global market 2027 forecast
- Basic Statistic Global pharmaceutical revenue by technology 2012-2026
- Basic Statistic Worldwide Rx drug sales excluding generics and orphan drugs 2012-2026
- Basic Statistic Projection of global revenue for orphan prescription drugs 2016-2028
- Basic Statistic Worldwide generic prescription drug sales 2012-2026
- Premium Statistic Revenue of the OTC pharmaceuticals industry worldwide 2018-2029
- Premium Statistic Global oncology spending 2013-2024
Companies
8
- Premium Statistic Top 50 pharmaceutical companies - Rx sales and R&D spending 2022
- Premium Statistic Top 10 biotech and pharmaceutical companies based on market cap 2024
- Basic Statistic Global pharma market share by top companies 2022
- Premium Statistic Pfizer's total revenue 2006-2023
- Premium Statistic Roche Group's total sales 2006-2023
- Premium Statistic Johnson & Johnson's total sales 2005-2023
- Basic Statistic AbbVie's revenue 2010-2023
- Basic Statistic Projected top pharmaceutical companies based on new sales 2023
R&D, patents, new products
8
- Premium Statistic Total global pharmaceutical R&D spending 2014-2028
- Basic Statistic Global top pharmaceutical companies based on R&D spending 2026
- Premium Statistic Patent expiration risks for total worldwide prescription drug revenue 2023-2028
- Basic Statistic Worldwide prescription drug revenue - market risk from patent expiration 2023-2028
- Premium Statistic Pharmaceutical industry - number of new substances 1998-2022
- Basic Statistic Pharma companies worldwide with active R&D pipelines 2001-2024
- Premium Statistic Number of novel drugs approved annually by CDER 2008-2023
- Basic Statistic Projected most valuable R&D projects based on net present value 2023
Outlook
7
- Premium Statistic World pharmaceutical sales by region forecast 2027
- Premium Statistic Global spending on medicines 2010-2027
- Premium Statistic CAGR by product type in pharmaceutical markets forecast 2023-2027
- Basic Statistic Country comparison in spending on medicine 2026
- Basic Statistic Top global biopharma drugs by lifetime sales up to 2028
- Basic Statistic Sales forecast of top pharmaceutical companies worldwide 2028
- Premium Statistic Sales forecast of top selling drugs worldwide 2028
Focus: COVID-19 response
6
- Basic Statistic Biotechs: duration of COVID-19 response compared to previous health threats 2003-2019
- Premium Statistic BARDA funding for the development of COVID-19 vaccines in the U.S. 2021
- Premium Statistic Shareholdings at select COVID-19 vaccine companies by investor 2021
- Premium Statistic Top companies by COVID-19 treatment vaccines in development June 2022
- Basic Statistic Comparison of select COVID-19 vaccines 2022, by efficacy
- Premium Statistic Distribution of COVID-19 vaccines worldwide by mechanism and phase 2022
Further related statistics
10
- Employer firm revenue of residential care and nursing facilities by tax category 2021
- Key figures on established biotech centers worldwide 2012-2016
- Cost savings through urgent care vs emergency department 2012
- Net earnings of UnitedHealth Group 2007-2023
- Medicaid long-term care services expenditures by type of service 1990-21
- Deaths by motor vehicle-related injuries in the U.S. 1930-2022
- Deaths by prostate cancer in the U.S. 1950-2019
- New cases of mumps in the U.S. 1970-2019
- New cases of shigellosis in the U.S. 1950-2019
- Rate of new cases of tuberculosis in the U.S. 1960-2019
Further Content: You might find this interesting as well
Statistics
- Employer firm revenue of residential care and nursing facilities by tax category 2021
- Key figures on established biotech centers worldwide 2012-2016
- Cost savings through urgent care vs emergency department 2012
- Net earnings of UnitedHealth Group 2007-2023
- Medicaid long-term care services expenditures by type of service 1990-21
- Deaths by motor vehicle-related injuries in the U.S. 1930-2022
- Deaths by prostate cancer in the U.S. 1950-2019
- New cases of mumps in the U.S. 1970-2019
- New cases of shigellosis in the U.S. 1950-2019
- Rate of new cases of tuberculosis in the U.S. 1960-2019
GlobalData. (January 1, 2016). Combined epidemiology of chronic hepatitis B in 8 major pharmaceutical markets in 2014* [Graph]. In Statista. Retrieved June 16, 2024, from https://www.statista.com/statistics/648514/epidemiology-of-chronic-hepatitis-b-in-major-pharma-markets/
GlobalData. "Combined epidemiology of chronic hepatitis B in 8 major pharmaceutical markets in 2014*." Chart. January 1, 2016. Statista. Accessed June 16, 2024. https://www.statista.com/statistics/648514/epidemiology-of-chronic-hepatitis-b-in-major-pharma-markets/
GlobalData. (2016). Combined epidemiology of chronic hepatitis B in 8 major pharmaceutical markets in 2014*. Statista. Statista Inc.. Accessed: June 16, 2024. https://www.statista.com/statistics/648514/epidemiology-of-chronic-hepatitis-b-in-major-pharma-markets/
GlobalData. "Combined Epidemiology of Chronic Hepatitis B in 8 Major Pharmaceutical Markets in 2014*." Statista, Statista Inc., 1 Jan 2016, https://www.statista.com/statistics/648514/epidemiology-of-chronic-hepatitis-b-in-major-pharma-markets/
GlobalData, Combined epidemiology of chronic hepatitis B in 8 major pharmaceutical markets in 2014* Statista, https://www.statista.com/statistics/648514/epidemiology-of-chronic-hepatitis-b-in-major-pharma-markets/ (last visited June 16, 2024)
Combined epidemiology of chronic hepatitis B in 8 major pharmaceutical markets in 2014* [Graph], GlobalData, January 1, 2016. [Online]. Available: https://www.statista.com/statistics/648514/epidemiology-of-chronic-hepatitis-b-in-major-pharma-markets/